Literature DB >> 7157458

Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome.

K Yokochi, A Yokochi, K Chiba, T Ishizaki.   

Abstract

We analyzed Michaelis--Menten pharmacokinetic parameters of phenytoin with and without the coadministration of allopurinol (150 and 200 mg/day) in a child with Lesch--Nyhan syndrome. The Vmax and Km were estimated from at least two different sets of serum concentration--dosage data of phenytoin. The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml). Our results suggest that allopurinol is a drug that inhibits the hepatic metabolism of phenytoin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7157458

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

Review 1.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of allopurinol.

Authors:  G A Murrell; W G Rapeport
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 3.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

4.  Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.

Authors:  S G O'Brien; P Meinhardt; E Bond; J Beck; B Peng; C Dutreix; G Mehring; S Milosavljev; C Huber; R Capdeville; T Fischer
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.